Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase

Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4

Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer

Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase

LIBRETTO-321, a phase 2 study of the efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancer (TC)

Sitravatinib + Tislelizumab in Patients with Anti-PD-(L)1 Refractory/Resistant Metastatic Non-small Cell Lung Cancer (NSCLC)

Sitravatinib + Tislelizumab in Patients with Metastatic Non-small Cell Lung Cancer (NSCLC)

Molecular testing, treatment and outcome of patients with advanced solid tumors harboring a NTRK1, NTRK2 or NTRK3 gene fusion - Study design and first results of the REALTRK registry

MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

STELLAR-001: a phase 1 study of the anti-C5aR avdoralimab in combination with the anti-PD-L1 durvalumab in advanced solid tumors.

A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors

Alofanib in subsequent therapy of advanced gastric cancer: Final results from the phase Ib clinical trial